Zyn-Linkertm/Heparin Conjugate to Prevent Restenosis

Award Information

Agency: Department of Health and Human Services	Branch: N/A	Award ID: 19320	Program Year/Program: 1995 / SBIR
Agency Tracking Number: 19320	Solicitation Year: N/A	Solicitation Topic Code: N/A	Solicitation Number: N/A

Small Business Information: Zynaxis, Inc.
371 PHOENIXVILLE PIKE MALVERN, PA 19355
View profile »

Woman-Owned: No

Minority-Owned: No

HUBZone-Owned: No

Phase 2: Fiscal Year: 1995

Title: Zyn-Linkertm/Heparin Conjugate to Prevent Restenosis

Agency: HHS

Contract: N/A

Award Amount: $686,168.00

Abstract:
RISK ASSESSMENT FOR CHRONIC HEART DISEASE (CHD) USES INDIRECT ESTIMATES OF LDL CHOLESTEROL FROM TOTAL CHOLESTEROL, HDL AND VLDL ESTIMATES. NO CLINICAL ASSAY EXISTS TO QUANTITATE LDL DIRECTLY FROM SERUM. WE WILL USE A MODEL LDL DETERMINATION ASSAY USING PKH26-ZYN-LINKER LABELLED LDL PARTICLES (LDLS) TO QUANTIFY LDLS DIRECTLY RATHER THAN USING TRADITIONAL PRECIPITATION TYPE ASSAYS AND CALCULATED LDL VALUES. PHASE I'S SPECIFIC AIMS ARE: 1) COMPARISON OF PKH26 ZYN-LINKER LDLS TO COMMERICALLY AVAILABLE LDLS USING PHYSICAL PROPERTIES SUCH AS DENSITY, STABILITY, DYE TO PARTICLE RATIOS AND FUNCTIONAL PROPERTIES (E.G. LDL RECEPTOR BINDING); 2) GENERATION OF SOLID SUBSTRATES SPECIFICALLY ABLE TO REACT WITH NORMAL AND MUTANT LDL PARTICLES; AND 3) CREATION OF A MODEL ASSAY TO DIRECTLY MEASURE LDL CONCENTRATIONS. THE ASSAY WILL BE BASED UPON COMPETITIVE BINDING OF PATIENT LDLS WITH REAGENT PARTICLES AND SIGNALS WILL BE DETECTED USING SPECTROFLUOROMETRIC METHODS.

Principal Investigator:
Gregory A Kopia
2158892200

Business Contact:

Small Business Information at Submission:

Zynaxis, Inc.
371 Phoenixville Pike Malvern, PA 19355

EIN/Tax ID:

DUNS: N/A

Number of Employees: N/A

Woman-Owned: No

Minority-Owned: No

HUBZone-Owned: No